Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets
Identifieur interne : 001F35 ( Main/Merge ); précédent : 001F34; suivant : 001F36Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets
Auteurs : Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-02-15.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Benzothiazoles (therapeutic use), Callithrix, Carbidopa (therapeutic use), Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Therapy, Combination (methods), Dyskinesias (drug therapy), Dyskinesias (etiology), Levodopa (therapeutic use), L‐dopa, MPTP, MPTP Poisoning (complications), Male, Motor Activity (drug effects), Parkinson's disease, Time Factors, dyskinesia, motor disability, pramipexole, primate.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Benzothiazoles, Carbidopa, Levodopa.
- complications : MPTP Poisoning.
- drug effects : Motor Activity.
- drug therapy : Dyskinesias.
- etiology : Dyskinesias.
- methods : Drug Therapy, Combination.
- Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Time Factors.
Abstract
Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22960
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001161
- to stream Istex, to step Curation: 001161
- to stream Istex, to step Checkpoint: 000778
- to stream PubMed, to step Corpus: 001A13
- to stream PubMed, to step Curation: 001A13
- to stream PubMed, to step Checkpoint: 001696
- to stream Ncbi, to step Merge: 002989
- to stream Ncbi, to step Curation: 002989
- to stream Ncbi, to step Checkpoint: 002989
Links to Exploration step
ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title>
<author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22960</idno>
<idno type="url">https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001161</idno>
<idno type="wicri:Area/Istex/Curation">001161</idno>
<idno type="wicri:Area/Istex/Checkpoint">000778</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Tayarani Inazir K:pramipexole:combined:with</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20108359</idno>
<idno type="wicri:Area/PubMed/Corpus">001A13</idno>
<idno type="wicri:Area/PubMed/Curation">001A13</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001696</idno>
<idno type="wicri:Area/Ncbi/Merge">002989</idno>
<idno type="wicri:Area/Ncbi/Curation">002989</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002989</idno>
<idno type="wicri:Area/Main/Merge">001F35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title>
<author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-02-15">2010-02-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="377">377</biblScope>
<biblScope unit="page" to="384">384</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno>
<idno type="DOI">10.1002/mds.22960</idno>
<idno type="ArticleID">MDS22960</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzothiazoles (therapeutic use)</term>
<term>Callithrix</term>
<term>Carbidopa (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Dyskinesias (drug therapy)</term>
<term>Dyskinesias (etiology)</term>
<term>Levodopa (therapeutic use)</term>
<term>L‐dopa</term>
<term>MPTP</term>
<term>MPTP Poisoning (complications)</term>
<term>Male</term>
<term>Motor Activity (drug effects)</term>
<term>Parkinson's disease</term>
<term>Time Factors</term>
<term>dyskinesia</term>
<term>motor disability</term>
<term>pramipexole</term>
<term>primate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzothiazoles</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Male</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.22960"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title>
<author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22960</idno>
<idno type="url">https://api.istex.fr/document/F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001161</idno>
<idno type="wicri:Area/Istex/Curation">001161</idno>
<idno type="wicri:Area/Istex/Checkpoint">000778</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Tayarani Inazir K:pramipexole:combined:with</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets</title>
<author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-02-15">2010-02-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="377">377</biblScope>
<biblScope unit="page" to="384">384</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83</idno>
<idno type="DOI">10.1002/mds.22960</idno>
<idno type="ArticleID">MDS22960</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term>
<term>MPTP</term>
<term>Parkinson's disease</term>
<term>dyskinesia</term>
<term>motor disability</term>
<term>pramipexole</term>
<term>primate</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa‐primed MPTP‐treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D‐2/D‐3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non‐dyskinetic MPTP‐treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04–0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125–6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1–0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy. © 2010 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.</title>
<author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.22960</idno>
<idno type="RBID">pubmed:20108359</idno>
<idno type="pmid">20108359</idno>
<idno type="wicri:Area/PubMed/Corpus">001A13</idno>
<idno type="wicri:Area/PubMed/Curation">001A13</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001696</idno>
<idno type="wicri:Area/Ncbi/Merge">002989</idno>
<idno type="wicri:Area/Ncbi/Curation">002989</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002989</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.</title>
<author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name>
</author>
<author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
</author>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzothiazoles (therapeutic use)</term>
<term>Callithrix</term>
<term>Carbidopa (therapeutic use)</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Dyskinesias (drug therapy)</term>
<term>Dyskinesias (etiology)</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP Poisoning (complications)</term>
<term>Male</term>
<term>Motor Activity (drug effects)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzothiazoles</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Male</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa-primed MPTP-treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D-2/D-3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non-dyskinetic MPTP-treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04-0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125-6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1-0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001F35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:F3BA2EBE96C85E58127A13D73CE92A1FDD6A7C83 |texte= Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |